Promising studies suggested sHLA-G as tolerogenic in MS pathogenesis: higher levels of sHLA-G in the cerebrospinal fluid (CSF) of patients with MS were positively correlated with less inflammation and no disease activity at MRI detection (7, 20, 21), whereas lower serum sHLA-G levels were found in patients with MS having clinically active disease (22). The gene discussed is HLA-G; the disease is myeloid sarcoma.